These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3856563)

  • 21. Early synergistic interactions between amikacin and six beta-lactam antibiotics against multiply resistant members of the family Enterobacteriaceae.
    Glew RH; Pavuk RA
    Antimicrob Agents Chemother; 1984 Sep; 26(3):378-81. PubMed ID: 6508266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro antibacterial activity of ceftizoxime.
    Andreoni O; Andreoni S; Molinari GL; Farinetti F
    Chemioterapia; 1985 Apr; 4(2):161-5. PubMed ID: 3859380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of ceftizoxime with azlocillin, mezlocillin, piperacillin and ticarcillin.
    Neu HC
    J Antimicrob Chemother; 1982 Nov; 10 Suppl C():63-8. PubMed ID: 6296031
    [No Abstract]   [Full Text] [Related]  

  • 24. Forecast of antibiotic susceptibility of translocating strains of enterobacteria and pseudomonas in leukemic neutropenic patients.
    Tancrède CH; Andremont AO
    Prog Clin Biol Res; 1985; 181():275-7. PubMed ID: 4022983
    [No Abstract]   [Full Text] [Related]  

  • 25. Antibacterial activity of temocillin.
    Malottke R; Potel J
    Drugs; 1985; 29 Suppl 5():67-73. PubMed ID: 3849426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Microbiological studies with the new penicillin BRL 17421 (temocillin)].
    Malottke R; Potel J
    Infection; 1983; 11(1):47-51. PubMed ID: 6302007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of third generation cephalosporins combined with amikacin against Pseudomonas aeruginosa.
    Rodríguez JR; Hernández NI; Ramírez-Ronda CH; Nevárez M
    Bol Asoc Med P R; 1985 Jun; 77(6):242-4. PubMed ID: 3931655
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical efficacy of a synergistic combination of cefotaxime and amikacin against multiresistant Pseudomonas and Serratia infections.
    Maslow MJ; Simberkoff MS; Rahal JJ
    J Antimicrob Chemother; 1985 Aug; 16(2):227-34. PubMed ID: 3934125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative activity of ceftizoxime against aminoglycoside-resistant aerobic gram-negative bacilli.
    Gómez-Lus R; Rubio MC; García C; Gómez-Lus ML; Alejandre MC
    Drugs Exp Clin Res; 1987; 13(3):155-9. PubMed ID: 3497792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cefotaxime plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with hematologic malignancies.
    Martino P; Venditti M; Petti MC; Mandelli F; Serra P
    Infection; 1985; 13(3):125-9. PubMed ID: 3928495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bactericidal activity and killing rate of serum from volunteers receiving pefloxacin alone or in combination with amikacin.
    Van der Auwera P; Klastersky J; Lieppe S; Husson M; Lauzon D; Lopez AP
    Antimicrob Agents Chemother; 1986 Feb; 29(2):230-4. PubMed ID: 3087276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escherichia coli infections in knee joints. The pharmacological and antibacterial effects of intramuscular antibiotics.
    Schurman DJ; Kajiyama G; Nagel DA
    J Bone Joint Surg Am; 1980; 62(4):620-7. PubMed ID: 6991503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complementary activity of mezlocillin and the combination of amoxicillin with clavulanic acid on Enterobacteriaceae.
    Roy C; Foz A; Tirado M; Fuster C; Segura C
    Infection; 1982; 10 Suppl 3():S262-6. PubMed ID: 6218121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The effect of sulbactam on the in vitro activity of mezlocillin, piperacillin and cefotaxime].
    Bauernfeind A; Grimm H; Klietmann W; Opferkuch W; Werner H
    Arzneimittelforschung; 1991 Aug; 41(8):831-8. PubMed ID: 1781806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparison of the antibacterial activity of amikacin (BB-K8) with other aminoglycosides against pathogens recently isolated from clinical materials (author's transl) ].
    Kosakai N; Oguri T
    Jpn J Antibiot; 1975 Aug; 28(4):530-7. PubMed ID: 240047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cefepime and amikacin synergy against a cefotaxime-susceptible strain of Enterobacter cloacae in vitro and in vivo.
    Mimoz O; Jacolot A; Padoin C; Caillon J; Louchahi K; Tod M; Samii K; Petitjean O
    J Antimicrob Chemother; 1997 Mar; 39(3):363-9. PubMed ID: 9096186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced in-vitro bactericidal activity of amikacin combined with latamoxef, cefotaxime and aztreonam against multi-resistant Enterobacter cloacae.
    Giamarellou H; Evagelopoulou V; Lelekis M
    J Antimicrob Chemother; 1989 Apr; 23(4):537-45. PubMed ID: 2787316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo action of mezlocillin and azlocillin combined with sisomicin.
    Dzierzanowska D; Jeljaszewicz J
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1983 Sep; 255(2-3):346-55. PubMed ID: 6417945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the in vitro activities of BB-K8 and three other aminoglycosides against 215 strains of Pseudomonas and Enterobacteriaceae with variable sensitivity to kanamycin and gentamicin.
    Yourassowsky E; Schoutens E; Vanderlinden MP
    Chemotherapy; 1975; 21(1):45-51. PubMed ID: 807457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical laboratory approach for estimating effective administrative dose of ceftizoxime. Observation from MIC and ceftizoxime disc susceptibility test].
    Uete T; Matsuo K
    Jpn J Antibiot; 1987 Feb; 40(2):331-9. PubMed ID: 3474430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.